Evidence map›Paper›PMID 42437182›Full record

ReviewAmerican heart journal plus : cardiology research and practice2026

Impact of SGLT2 inhibitors in cardiac amyloidosis: A systematic review and meta-analysis.

Shreyas Nandyal, Aviral Vij, Revati Varma, Rohan Gajjar, Angelo Caputi, Samuel Odoi, Sukriti Banthiya, Saketh Vinjamuri, Saurabh Malhotra

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in American heart journal plus : cardiology research and practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Shreyas NandyalDepartmeent of Internal Medicine, John H. Stroger, Jr. Hospital of Cook County, Chicago, IL, USA.
Aviral VijDepartmeent of Internal Medicine, John H. Stroger, Jr. Hospital of Cook County, Chicago, IL, USA.
Revati VarmaDepartmeent of Internal Medicine, John H. Stroger, Jr. Hospital of Cook County, Chicago, IL, USA.
Rohan GajjarDepartmeent of Internal Medicine, John H. Stroger, Jr. Hospital of Cook County, Chicago, IL, USA.
Angelo CaputiDepartmeent of Internal Medicine, John H. Stroger, Jr. Hospital of Cook County, Chicago, IL, USA.
Samuel OdoiDepartmeent of Internal Medicine, John H. Stroger, Jr. Hospital of Cook County, Chicago, IL, USA.
Sukriti BanthiyaDepartment of Internal Medicine, Henry Ford Hospital - Providence, Southfield, MI, USA.
Saketh VinjamuriDepartment of Internal Medicine, Gandhi Medical College - Secunderabad, TS, India.
Saurabh MalhotraDivision of Cardiology, John H. Stroger, Jr. Hospital of Cook County, Chicago, IL, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Cardiac amyloidosis (CA), including transthyretin (ATTR) and light-chain (AL) subtypes, is an underrecognized mimic of heart failure with preserved ejection fraction. While sodium-glucose cotransporter-2 inhibitors (SGLT2i) benefit general heart failure (HF) populations, their role in CA is unclear. This study evaluated the impact of SGLT2i on outcomes in patients with CA. Methods: A systematic review and meta-analysis of seven observational studies ( Results: In the primary analysis restricted to ATTR-CA, SGLT2i use was associated with lower observed all-cause mortality (the primary outcome; HR 0.71, 95% CI 0.58-0.87, Conclusions: In this meta-analysis of non-randomized observational studies, SGLT2 inhibitor use was associated with lower observed mortality and improved cardiac biomarkers in CA, with renal benefits most evident in ATTR. Because all included studies were observational and susceptible to confounding by indication, immortal time bias, and survivor bias, these findings are hypothesis-generating and should not be interpreted as evidence of efficacy; randomized trials are needed before treatment recommendations can be made.

Indexed as

Cardiac amyloidosisHeart failureMeta-analysisSodium-glucose cotransporter-2 inhibitorsSystematic review

Identifiers

PMID42437182
PMCPMC13355794

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.